Form D · Pharmaceuticals
Capacity Bio, Inc.
Palo Alto, CA · CIK 0001960587
Offering snapshot reported Jan 18, 2023 · SEC filing
- Reported sold
- $19.2M Offering amount: $35.3M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 21, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 18, 2023 | Initial | $19,210,937 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-470977
Source: Form D, filed Jan 18, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cristina Ghenoiu | Director |
| Kenneth Horne | Director, Executive |
| Taro Inaba | Director |
| Dylan Morris | Director |
| Amy Wang | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3175 Hanover St.
Palo Alto, CA, 94304
Palo Alto, CA, 94304